Skip to main content

Table 2 Network meta-analysis of lymphocyte subsets levels in COVID-19 patients with different clinical stages MD (95%CI)

From: Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis

Comparisons CD3+ (/μL) CD4+ (/μL) CD8+ (/μL) CD19+ (/μL) CD16+ CD56+ (/μL)
Severe VS. Mild a −389.02 (− 549.59, − 228.45) −198.74 (− 262.12, −135.35) −127.49 (− 173.75, − 81.24) − 134.32 (− 203.92, − 64.71) − 23.27 (− 55.79, 9.25)
Critical VS. Mild a −479.87 (− 696.64, − 263.10) − 262.18 (− 356.76, − 167.60) − 159.06 (− 223.91, − 94.22) −173.38 (− 289.84, − 56.91) −57.68 (− 101.37, − 14.00)
Critical VS. Severe a −90.85 (− 305.37, 123.67) −63.44 (− 157.51, 30.62) − 31.57 (− 96.09, 32.95) −39.06 (− 155.12, 76.99) − 34.41 (− 78.91, 10.08)
Inconsistency P-value 0.135 0.081 0.049 0.279 0.639
  1. aWhen comparing, the groups in the later positions were taken as the reference
  2. Abbreviation: CD cluster of differentiation
\